Designs for Group Sequential Phase II Clinical Trials

DOI10.2307/2531540zbMATH Open0715.62244OpenAlexW2316588149WikidataQ52583941 ScholiaQ52583941MaRDI QIDQ3201547FDOQ3201547

Harry S. Wieand, Terry M. Therneau, Stephan S. Cha, Myron N. Chang

Publication date: 1987

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.2307/2531540

Recommendations

• Approximately optimal designs for phase II clinical studies
• Optimal two-stage group-sequential designs
• Computation of optimal group sequential designs
• Two-stage group sequential designs for comparative clinical trials
• Optimal Designs for a Grouped Sequential Binomial Trial

zbMATH Keywords

clinical trialsoptimal design

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical design (62L05)

Cited In (19)

• Nearly optimal truncated group sequential test on binomial proportions
• An Optimal Design for Screening Trials
• Optimal Designs for a Grouped Sequential Binomial Trial
• On the maximum total sample size of a group sequential test about bivariate binomial propor\-tions
• MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION
• Exact confidence limits after a group sequential single arm binary trial
• On the maximum total sample size of a group sequential test about binomial proportions.
• Approximately optimal designs for phase II clinical studies
• Design and Analysis of Phase II Cancer Trials: A Review of Statistical Methods and Guidelines for Medical Researchers
• Two-Stage Designs with Additional Futility Tests for Phase II Clinical Trials with Heterogeneous Patient Populations
• Methodology and application of adaptive and sequential approaches in contemporary clinical trials
• Two-stage group sequential designs for comparative clinical trials
• On Bayesian estimators in multistage binomial designs
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
• A class of confidence intervals for sequential phase II clinical trials with binary outcome
• Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity
• Improving the Flexibility and Efficiency of Phase II Designs for Oncology Trials
• Assurance test and its equivalent truncated sequential test
• A review of phase 2-3 clinical trial designs

This page was built for publication: Designs for Group Sequential Phase II Clinical Trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3201547)